Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma ( LBCL): Primary Analysis of a Phase Ib/II Study

被引：7

作者：

Budde, L. Elizabeth ^{[1
]}

Olszewski, Adam J. ^{[2
]}

Assouline, Sarit ^{[3
]}

Lossos, Izidore S. ^{[4
]}

Diefenbach, Catherine ^{[5
]}

Kamdar, Manali ^{[6
]}

Ghosh, Nilanjan ^{[7
]}

Modi, Dipenkumar ^{[8
]}

Sabry, Waleed ^{[9
]}

Naik, Seema ^{[10
]}

Mehta, Amitkumar ^{[11
]}

Nakhoda, Shazia K. ^{[12
]}

Smith, Stephen D. ^{[13
]}

Dorritie, Kathleen ^{[14
]}

Jia, Ting ^{[15
]}

Pham, Song ^{[16
]}

Huw, Ling-Yuh ^{[17
]}

Wu, Hao ^{[17
]}

To, Iris ^{[17
]}

Wei, Michael C. ^{[17
]}

Chavez, Julio C. ^{[18
]}

机构：

[1] City Hope Natl Med Ctr, Duarte, CA USA

[2] Brown Univ, Lifespan Canc Inst, Legorreta Canc Ctr, Providence, RI USA

[3] McGill Univ, Jewish Gen Hosp, Montreal, PQ, Canada

[4] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[5] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA

[6] Univ Colorado, Aurora, CO USA

[7] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[8] Wayne State Univ, Barbara Ann Karmanos Canc Inst, Detroit, MI USA

[9] Univ Saskatchewan, Saskatoon Canc Ctr, Coll Med, Saskatoon, SK, Canada

[10] Penn State Canc Inst, Hershey, PA USA

[11] Univ Alabama Birmingham, Birmingham, AL USA

[12] Fox Chase Canc Ctr, Philadelphia, PA USA

[13] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA

[14] Univ Pittsburgh, UPMC Hillman Canc Ctr, Pittsburgh, PA USA

[15] Roche China Holding Ltd, Shanghai, Peoples R China

[16] F Hoffmann Roche Ltd, Basel, Switzerland

[17] Genentech Inc, San Francisco, CA USA

[18] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-174209

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 50 条

[1] Mosunetuzumab with Polatuzumab Vedotin: Subgroup Analyses in Patients (pts) With Primary Refractory or Early Relapsed Large B-Cell Lymphoma (LBCL)
Assouline, Sarit
Budde, Lihua Elizabeth
Chavez, Julio C.
Diefenbach, Catherine S.
Dorritie, Kathleen Anne
Ghosh, Nilanjan
Olszewski, Adam J.
Lossos, Izidore S.
Mehta, Amitkumar
Modi, Dipenkumar
Naik, Seema
Smith, Stephen Douglas
Makadia, Sneha
Pham, Song
Wu, Hao
Batlevi, Connie Lee
To, Iris
Wei, Michael C.
Kamdar, Manali
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S461 - S461
[2] Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL)
Assouline, Sarit
Budde, Lihua Elizabeth
Chavez, Julio C.
Diefenbach, Catherine S.
Dorritie, Kathleen Anne
Ghosh, Nilanjan
Olszewski, Adam J.
Lossos, Izidore S.
Mehta, Amitkumar
Modi, Dipenkumar
Naik, Seema
Smith, Stephen Douglas
Makadia, Sneha
Pham, Song
Wu, Hao
Batlevi, Connie Lee
To, Iris
Wei, Michael C.
Kamdar, Manali
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[3] Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study
Gritti, Giuseppe
Marlton, Paula
Phillips, Tycel J.
Arthur, Christopher
Bannerji, Rajat
Corradini, Paolo
Johnston, Anna
Seymour, John F.
Yuen, Sam
Hirata, Jamie
Musick, Lisa
Saha, Sourish
Croft, Brandon
Flowers, Christopher
BLOOD, 2020, 136
[4] Glofitamab plus Polatuzumab Vedotin demonstrates durable responses and a manageable safety profile in patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Dietrich, S.
Hutchings, M.
Avigdor, A.
Sureda, A.
Terol, M. J.
Bosch, F.
Corradini, P.
Larsen, Stauffer T.
Dominguez, Rueda A.
Skarbnik, A.
Jorgensen, J.
Goldschmidt, N.
Gurion, R.
Zinzani, P. L.
Pinto, A.
Cordoba, R.
Bottos, A.
Huang, Z.
Simko, S.
Relf, J.
de L'Etang, Filezac A.
Sellam, G.
Gritti, G.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 209 - 209
[5] Updated results of a phase Ib/II randomised study: polatuzumab vedotin (Pola) plus bendamustine (B) and rituximab (R) in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
Sehn, L. H.
McMillan, A.
Matasar, M. J.
Flowers, C. R.
Kamdar, M.
Hertzberg, M.
Assouline, S.
Kim, T. M.
Kim, W. S.
Ozcan, M.
Croft, B.
Herrera, A. F.
Hirata, J.
Cheng, J.
Ku, G.
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 93 - 94
[6] Updated results from a phase Ib/II study in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) treated with polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G)
McMillan, A.
Sehn, L.
Herrera, A.
Matasar, M.
Kamdar, M.
Assouline, S.
Hertzberg, M.
Kim, T. M.
Kim, W. S.
Ozcan, M.
Hirata, J.
Penuel, E.
Cheng, J.
Ku, G.
Flowers, C.
BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 80 - 80
[7] Updated results from a phase Ib/II study in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) treated with polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G)
Glass, B.
Sehn, L. H.
Herrera, A. F.
Matasar, M.
Kamdar, M.
Assouline, S.
Hertzberg, M.
Kim, T. M.
Kim, W. S.
McMillan, A.
Ozcan, M.
Hirata, J.
Penuel, E.
Cheng, J.
Ku, G.
Flowers, C. R.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 3 - 3
[8] Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and ≥65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and ≥1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study
Olszewski, Adam J.
Budde, L. Elizabeth
Chavez, Julio
Ghosh, Nilanjan
Kamdar, Manali
Lossos, Izidore S.
Diefenbach, Catherine
Sabry, Waleed
Dorritie, Kathleen
Huw, Ling-Yuh
Pham, Song
Jia, Ting
Wu, Hao
To, Iris
Wei, Michael C.
Assouline, Sarit
BLOOD, 2022, 140 : 3757 - 3758
[9] Polatuzumab vedotin (Pola) plus rituximab (R) plus lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial.
Diefenbach, Catherine S. Magid
Abrisqueta, Pau
Gonzalez-Barca, Eva
Panizo, Carlos
Perez, Jose Maria Arguinano
Miall, Fiona
Bastos-Oreiro, Mariana
Lopez-Guillermo, Armando
Banerjee, Lalita
McMillan, Andrew
Hirata, Jamie
Musick, Lisa
Saha, Sourish
Croft, Brandon
Seymour, Erlene Kuizon
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[10] Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study
Sehn, Laurie H.
Herrera, Alex F.
Matasar, Matthew J.
Kamdar, Manali
Assouline, Sarit
Hertzberg, Mark
Kim, Tae Min
Kim, Won-Seog
McMillan, Andrew
Ozcan, Muhit
Hirata, Jamie M.
Penuel, Elicia
Cheng, Ji
Ku, Grace
Flowers, Christopher R.
BLOOD, 2018, 132

← 1 2 3 4 5 →